Evidence map›Paper›PMID 28332133›Full record

ArticleFolia microbiologica2017

Molecular typing and antimicrobial susceptibility testing to six antimicrobials of Clostridium difficile isolates from three Czech hospitals in Eastern Bohemia in 2011-2012.

V Beran, E J Kuijper, C Harmanus, I M Sanders, S M van Dorp, C W Knetsch, J Janeckova, A Seidelova, L Barekova, J Tvrdik and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Folia microbiologica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. High Prevalence ofPathogens (Basel, Switzerland) · 2023
    Article
  4. Fidaxomicin for the Treatment ofAntibiotics (Basel, Switzerland) · 2022
    Review
  5. Observational
  6. Novel Antimicrobials for the Treatment ofFrontiers in medicine · 2018
    Review
  7. Antibiotic Resistance and Toxin Production ofFrontiers in microbiology · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

V BeranCzech Anaerobic Bacteria Reference Laboratory, Department of Biomedical Sciences, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic. vladimir.beran@osu.cz.ORCID http://orcid.org/0000-0001-8702-6606
E J KuijperDepartment of Medical Microbiology, Leiden University Medical Centre, Leiden, Netherlands.
C HarmanusDepartment of Medical Microbiology, Leiden University Medical Centre, Leiden, Netherlands.
I M SandersDepartment of Medical Microbiology, Leiden University Medical Centre, Leiden, Netherlands.
S M van DorpDepartment of Medical Microbiology, Leiden University Medical Centre, Leiden, Netherlands.
C W KnetschDepartment of Medical Microbiology, Leiden University Medical Centre, Leiden, Netherlands.
J JaneckovaDepartment of Infection Diagnosis, Litomysl Hospital, The Hospital of Pardubice Region, Pardubice, Czech Republic.
A SeidelovaDepartment of Clinical Immunology and Microbiology, Regional Hospital of Nachod, Nachod, Czech Republic.
L BarekovaDepartment of Clinical Microbiology, Pardubice Hospital, The Hospital of Pardubice Region, Pardubice, Czech Republic.
J TvrdikDepartment of Computer Science, Faculty of Science, University of Ostrava, Ostrava, Czech Republic.
D ChmelarCzech Anaerobic Bacteria Reference Laboratory, Department of Biomedical Sciences, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
I CiznarCzech Anaerobic Bacteria Reference Laboratory, Department of Biomedical Sciences, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 2011-2012, a survey was performed in three regional hospitals in the Czech Republic to determine the incidence of Clostridium difficile infections (CDIs) and to characterize bacterial isolates. C. difficile isolates were characterized by PCR ribotyping, toxin genes detection, multiple-locus variable-number tandem-repeat analysis (MLVA), and antimicrobial susceptibility testing to fidaxomicin, vancomycin, metronidazole, clindamycin, LFF571, and moxifloxacin using agar dilution method. The incidence of CDI in three studied hospitals was 145, 146, and 24 cases per 100,000 inhabitants in 2011 and 177, 258, and 67 cases per 100,000 inhabitants in 2012. A total of 64 isolates of C. difficile was available for molecular typing and antimicrobial susceptibility testing. 60.9% of the isolates were classified as ribotype 176. All 41 isolates of ribotypes 176 and 078 were positive for the presence of binary toxin genes. Ribotype 176 also carried 18-bp deletion in the regulatory gene tcdC. Tested isolates of C. difficile were fully susceptible to vancomycin and metronidazole, whereas 65.1% of the isolates were resistant to moxifloxacin. MLVA results indicated that isolates from three different hospitals were genetically related, suggesting transmission between healthcare facilities.

Indexed as

Molecular TypingAnti-Bacterial AgentsBacterial ToxinsClostridioides difficileClostridium InfectionsCzech RepublicDisk Diffusion Antimicrobial TestsHospitalsHumansIncidenceMinisatellite RepeatsRibotypingAnti-Bacterial AgentsBacterial Toxins

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.